• 1
    Berndt TJ, Schiavi S, Kumar R 2005 “Phosphatonins” and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289: F1170F1182.
  • 2
    Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL 2005 Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol 23: 36263628.
  • 3
    Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA 2002 Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359: 761763.
  • 4
    Moran M, Paul A 2002 Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia. Int Orthop 26: 6162.
  • 5
    Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F 2001 Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345: 18831888.
  • 6
    Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB, Lim SK 2001 Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf) 54: 551554.
  • 7
    Casari S, Rossi V, Varenna M, Gasparini M, Parafioriti A, Failoni S, Sinigaglia L 2003 A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol 21: 493496.
  • 8
    Nguyen BD, Wang EA 1999 Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med 24: 130131.
  • 9
    Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, Muller-Brand J, Hofmann M 2005 68Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32: 724.
  • 10
    Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC 2003 DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30: 13381347.
  • 11
    Walton RJ, Bijvoet OL 1975 Nomogram for derivation of renal threshold phosphate concentration. Lancet 2: 309310.
  • 12
    Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683692.
  • 13
    Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N, Kantelip B 2005 Oncogenic osteomalacia: Diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 36: 375378.
  • 14
    Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, Scolyer RA, Robinson BG, Mason RS, Bligh PC 2003 Clinical case seminar: Fibroblast growth factor 23: A new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 88: 40884094.
  • 15
    Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M 2004 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 31: 10971104.
  • 16
    Zasadny KR, Wahl RL 1993 Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189: 847850.
  • 17
    Crouzet J, Mimoune H, Beraneck L, Juan LH 1995 Hypophosphatemic osteomalacia with plantar neurilemoma. A review of the literature (100 cases). Rev Rhum Engl Ed 62: 463466.
  • 18
    Gonzalez-Compta X, Manos-Pujol M, Foglia-Fernandez M, Peral E, Condom E, Claveguera T, Dicenta-Sousa M 1998 Oncogenic osteomalacia: Case report and review of head and neck associated tumours. J Laryngol Otol 112: 389392.
  • 19
    Reis-Filho JS, Paiva ME, Lopes JM 2004 August 2003: 47-year-old female with a 7-year history of osteomalacia and hypophosphatemia. Brain Pathol 14: 111112, 115.
  • 20
    Sandhu FA, Martuza RL 2000 Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: Case report. J Neurooncol 46: 241247.
  • 21
    Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW 2004 Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28: 130.
  • 22
    Carpenter TO 2003 Oncogenic osteomalacia–a complex dance of factors. N Engl J Med 348: 17051708.
  • 23
    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 16561663.
  • 24
    Duet M, Liote F 2004 Somatostatin and somatostatin analog scintigraphy: Any benefits for rheumatology patients? Joint Bone Spine 71: 530535.
  • 25
    Ludwig J, Mechtersheimer G, Haberkorn U, Nawroth P, Schilling T, Kasperk C 2005 [Oncogenic osteomalacia in a 49-year-old female patient]. Dtsch Med Wochenschr 130: 206209.
  • 26
    Reubi JC, Waser B, Schaer JC, Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28: 836846.
  • 27
    Schmidt GP, Haug AR, Schoenberg SO, Reiser MF 2006 Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 16: 12161225.
  • 28
    Teunissen JJ, Kwekkeboom DJ, Krenning EP 2006 Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17: 1925.
  • 29
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP 2005 Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46: 62S66S.